50
Participants
Start Date
July 2, 2018
Primary Completion Date
June 27, 2022
Study Completion Date
June 27, 2022
Parsaclisib
Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
Rituximab
Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
Bendamustine
Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
Ibrutinib
Ibrutinib administered orally once daily.
Azienda Ospedaliera San Gerardo Di Monza, Monza
Asst Spedali Civili Di Brescia, Brescia
Fundacion Jimenez Diaz University Hospital, Madrid
Hospital Universitario Hm Sanchinarro, Madrid
Hospital Clinico Universitario de Salamanca, Salamanca
Hospital Universitario Virgen Del Rocio, Seville
Hospital Universitario Y Politecnic La Fe, Valencia
Indiana Blood and Marrow Transplantation, Indianapolis
Ospedale Delle Croci - Ematologia Ravenna, Ravenna
Azienda Ospedaliera Universitaria Pisana, Pisa
Baylor Charles A. Sammons Cancer Center, Dallas
Baylor College of Medicine, Houston
Smith Clinic, Houston
Cancer Care Centers of South Texas, San Antonio
Texas Oncology San Antonio, San Antonio
Texas Oncology, Austin
University of Arizona Cancer Center - Out Pt., Tucson
Comprehensive Cancer Center of Nevada, Las Vegas
Hospital Germans Trias I Pujol, Badalona
Hospital General Universitari Vall D Hebron, Barcelona
Hospital Clinic I Provincial, Barcelona
Lead Sponsor
Incyte Corporation
INDUSTRY